Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND , LEADER and SUSTAIN ‐6 to the real‐world type 2 diabetes population in the United Kingdom

Figures

• 

  FIGURE 1. Proportion of study cohort (N = 33 118) meeting cardiovascular (CV) or CV/core criteria for the three CV outcome trials

• 

  FIGURE 2. Proportion of the study cohort (N = 33 118) meeting each criterion for the three cardiovascular outcome trials (CVOTs) (A), and the proportion of patients who met cardiovascular (CV) entry criteria who also met each of the other core criteria (B). In (A) eligibility for the age core criterion was determined by eligibility for CV entry criteria. For estimated glomerular filtration rate (eGFR) the criterion was ≥15 mL/min/1.73 m2 at most recent measurement on or prior to the assessment date. *CVOT did not apply this core criterion. BMI, body mass index; HbA1c, glycated haemoglobin

• 

  FIGURE 3. Patient subclassification per cardiovascular (CV) outcome trial for “established CV disease (CVD)” vs. “CV risk factors” of study cohort (N = 33 118) (A), and for glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) users (N = 2056) (B). For patients satisfying both ‘established CVD’ and ‘CV risk factors’ criteria, the former took precedence